Thc Therapeutics, INC

THC Therapeutics, Inc. has successfully acquired 100% of The Headquarters Group, Inc. and its subsidiaries in an all-share transaction valued at approximately $11 million, significantly advancing its vertical integration and roll-up strategy in the legal cannabis industry.

THC Therapeutics files an amendment to its previous 8-K report to include a letter from Brandon Romanek, the former director, contesting his removal from the board.

THC Therapeutics announces the removal of Brandon Romanek from the Board of Directors and all positions held within the company, effective April 2, 2025.

THC Therapeutics has dismissed its auditor, Gries & Associates, after the Public Company Accounting Oversight Board revoked the firm's registration.

THC Therapeutics has dismissed its auditor, Gries & Associates, after the SEC revoked their registration, and has engaged Green Growth CPAs as their new independent accountant.

THC Therapeutics reported its financial results for the quarter ended April 30, 2024, highlighting a net income of $104,622, despite ongoing operating losses and a going concern qualification.

THC Therapeutics, Inc. reports its financial results for the quarter ended January 31, 2024, highlighting ongoing efforts to develop its dHydronator product amid going concern uncertainties.

THC Therapeutics reports no revenue for Q1 2024, but manages to decrease its operating loss compared to the same period last year, while still facing substantial doubt about its ability to continue as a going concern.

THC Therapeutics, Inc. reported its annual results, highlighting a focus on the development of its dHydronator herb dryer and ongoing financial challenges.